Pathophysiology of Haemostasis and Thrombosis

Original Paper

Differential Behavior of Coagulation Factor XIII in Patients with Inflammatory Bowel Disease and in Patients with Giant Cell Arteritis

Vrij A.A.a · Rijken J.b · van Wersch J.W.J.c · Stockbrügger R.W.a

Author affiliations

Department of aGastroenterology, University Hospital Maastricht, and Departments of bInternal Medicine and cHematology, Atrium Hospital Heerlen, The Netherlands

Keywords: Factor XIIIFibrinogenCrohn’s diseaseUlcerative colitisGiant cell arteritis

Related Articles for ""
Haemostasis 1999;29:326–335
https://doi.org/10.1159/000022520

Log in to MyKarger to check if you already have access to this content.




Forgot your password
Sign up to MyKarger

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

For eJournal Archive and eJournal Backfiles information please contact Karger service

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: June 15, 2000
Issue release date: November – December

Number of Print Pages: 10
Number of Figures: 3
Number of Tables: 1

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: https://www.karger.com/PHT

Abstract

The aim of this prospective study was to examine the role of coagulation factor XIII (FXIII) in relation to disease activity in inflammatory bowel disease (IBD) and in giant cell arteritis. Plasma FXIII activity was studied during active and inactive disease in newly diagnosed patients with Crohn’s disease (CD; n = 20), ulcerative colitis (UC; n = 18) and giant cell arteritis (GCA; n = 19), in 3-month intervals (median follow-up 12 months). FXIII was also measured in two noninflammatory control groups, age and sex matched for IBD (n = 25) and GCA (n = 26). FXIII activity was significantly lower in active CD or UC than in active GCA or the noninflammatory controls. Both in CD and UC, FXIII activity correlated inversely with indices of clinical disease activity, the erythrocyte sedimentation rate, fibrinogen and C-reactive protein levels. Low FXIII activity is a characteristic feature of active IBD, and serial measurements may be useful to assess IBD activity.

© 2000 S. Karger AG, Basel



Related Articles:

References

  1. Wakefield AJ, Sankey EA, Dhillon AP, Sawyerr AM, More L, Sim R, Pounder RE: Granulomatous vasculitis in Crohn’s disease. Gastroenterology 1991;100:1279–1287.
    External Resources
  2. Fairburn RA: Aetiology of ulcerative colitis: A vascular hypothesis. Lancet 1973;ii:697–699.
  3. Ritchie DG, Levy BA, Adams MA: Regulation of fibrinogen synthesis by plasmin-derived fragments of fibrinogen and fibrin: An indirect feedback pathway. Proc Natl Acad Sci USA 1982;79:1530–1534.
    External Resources
  4. Conlan MG, Haire WD, Burnett DA: Prothrombotic abnormalities in inflammatory bowel disease. Dig Dis Sci 1989;34:1089–1093.
    External Resources
  5. Stevens TRJ, James JP, Simmonds NJ, McCarthy DA, Laurenson IF, Maddison PJ, Rampton DS: Circulating von Willebrand factor in inflammatory bowel disease. Gut 1992;33:502–506.
    External Resources
  6. de Jong E, Prote RJ, Knot EAR, Verheijen JH, Dees L: Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa and faeces. Gut 1989;30:188–194.
    External Resources
  7. Van Wersch JWJ, Houben P, Rijken J: Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem 1990;28:513–517.
    External Resources
  8. Collins CE, Rampton DS: Platelet dysfunction: A new dimension in inflammatory bowel disease. Gut 1995;36:5–8.
    External Resources
  9. De Keyser J, De Klippel N, Ebinger G: Thrombocytosis and ischaemic complications in giant cell arteritis. BMJ 1991;303:825.
  10. Nordborg E, Andersson R, Tengborg L, Eden S, Bengtsson B: von Willebrand factor antigen and plasminogen activator inhibitor in giant cell arteritis. Ann Rheum Dis 1991;50:316–320.
    External Resources
  11. Vrij AA, Mazee HA, Lustermans FAT, van Wersch JWJ: Coagulation and fibrinolysis in polymyalgia rheumatica and giant cell arteritis. Neth J Med 1995;46:A47.
  12. Wisen O, Gardlund B: Hemostasis in Crohn’s disease: Low factor XIII levels in active disease. Scand J Gastroenterol 1988;23:961–966.
    External Resources
  13. Suzuki R, Toda H, Takamura Y: Dynamics of blood coagulation factor XIII in ulcerative colitis and preliminary study of the factor XIII concentrate. Blut 1989;59:162–164.
    External Resources
  14. Stadnicki A, Kloczoko J, Nowak A, Sierka E: Alterations of haemostasis parameters with special references to factor XIII and fibronectin in patients with ulcerative colitis. Eur J Gastroenterol Hepatol 1992;4:743–746.
  15. Hudson M, Murdock PJ, Wakefield AJ, Pounder RE, Lee CA: Factor XIII activity (FXIII) and antigen (FXIII) levels in inflammatory bowel disease. Thromb Haemost 1993;69:793.
  16. Chamouard P, Grunebaum L, Wiesel ML, Sibila J, Coumaros G, Wittersheim C, Baumann R, Cazenave JP: Significance of diminished factor XIII in Crohn’s disease. Am J Gastroenterol 1998;93:610–614.
    External Resources
  17. Hudson M, Wakefield AJ, Hutton RA, Sankey EA, Dhillon AP, More L, Sim R, Pounder RE: Factor XIIIA subunit and Crohn’s disease. Gut 1993;34:75–79.
    External Resources
  18. Ichinose A, Davie EW: Primary structure of human coagulation factor XIII. Adv Exp Med Biol 1988;231:15–27.
    External Resources
  19. Carmassi F, Uchino R, Cardanali M, Chung SI: Influence of FXIII mediated cross-link on extravascular fibrinolysis; in McDonagh J, Seitz R, Egbring R (eds): Factor XIII. Stuttgart, Schattauer, 1993, pp 9–16.
  20. McDonagh J: Biochemistry of fibrin-stabilizing factor (FXIII); in McDonagh J, Seitz R, Egbring R (eds): Factor XIII. Stuttgart, Schattauer, 1993, pp 2–8.
  21. Brown LF, Lanir N, McDonagh J, Tognazzi K, Dvorak HF: Fibroblast migration in fibrin gel matrices. Am J Pathol 1993;142:273–283.
    External Resources
  22. Stief TW: Factor XIII of blood coagulation inhibits the oxidative phagocyte metabolism and suppresses the immune response in vivo. Thromb Res 1991;63:227–238.
    External Resources
  23. Dempfle CE, Magez J, Röckel A, Gladisch R, Harenberg J, Heene DL: Acquired factor XIII deficiency and substitution of factor XIII in exacerbated ulcerative colitis and Crohn’s disease; in McDonagh J, Seitz R, Egbring R (eds): Factor XIII. Stuttgart, Schattauer, 1993, pp 181–192.
  24. Fukui H and the Japanese Pediatric Group: Clinical evaluation of a pasteurized factor XIII concentrate administration in Henoch Schönlein purpura. Thromb Res 1989;56:667–675.
    External Resources
  25. Lennard-Jones GE: Classification of inflammatory bowel disease. Scand J Gastroenterol 1989;24(suppl 170):2–6.
  26. Best WR, Becktel JM, Singleton JW, Kern F: Development of a Crohn’s disease Activity Index. Gastroenterology 1976;70:439–444.
    External Resources
  27. Truelove-Witts SS, Witts LJ: Cortisone in ulcerative colitis: Final report on a therapeutic trial. Br Med J 1955;ii:1042–1048.
  28. Hunder G, Bloch DA, Michel BA, Steven MB, Arend WP, Calbrese LH, Edworthy SM, Fauci AS, Leavitt RY, Lie JT, Lightfoot RW Jr, Masi AT, Mcshane DJ, Mills JA, Wallace SL, Zvaifler HJ: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990;33:1122–1128.
    External Resources
  29. Hazleman BL, Bengtsson B.-Å: Giant cell arteritis and polymyalgia rheumatica; in Hazleman BL, Bengtsson B.-Å (eds): Clinical Rheumatology, vol 5, No 3. London, Baillière Tindall, 1991, pp 371–378.
  30. Van Wersch JWJ: Analytical and clinical utility of a photometric assay for blood coagulation factor XIII. Eur J Clin Chem Clin Biochem 1993;31:467–471.
    External Resources
  31. Seitz R, Leugner F, Katschinski M, Immel A, Kraus M, Egbring R, Göke B: Ulcerative colitis and Crohn’s disease: Factor XIII. Inflammation and haemostasis. Digestion 1994;55:361–367.
    External Resources
  32. Lamers CBHW, Biemond I, van der Sluys Veer A, van Hogezand RA: Assessment of inflammatory activity in Crohn’s disease. Neth J Med 1994;45:52–54.
    External Resources
  33. Jullien D, Souillet AL, Faure M, Claudy A: Coagulation factor XIII in scleroderma. Eur J Dermatol 1998;8:231–234.
    External Resources
  34. Lorentz R, Born P, Classen M: Factor XIII substitution in ulcerative colitis. Lancet 1995;345:449.
    External Resources
  35. Bregenzer N, Caesar I, Andus T, Hämling J, Malchow H, Schreiber S, Schölmerich J, and the Factor XIII Study Group: Lack of clinical efficacy of additional factor XIII treatment in patients with steroid-refractory colitis. Z Gastroenterol 1999;37:999–1004.
    External Resources

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Published online: June 15, 2000
Issue release date: November – December

Number of Print Pages: 10
Number of Figures: 3
Number of Tables: 1

ISSN: 1424-8832 (Print)
eISSN: 1424-8840 (Online)

For additional information: https://www.karger.com/PHT

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Article Tools
Article Details

1999, Vol.29, No. 6

November – December

Article

Recommend This
TOP